Full course description
The KIND Cerebral Palsy (CP) course provides a comprehensive exploration of CP, beginning with its definition, epidemiology, and early risk factors. Building from foundational knowledge, the curriculum moves into early identification, hip screening and surveillance, and the multifaceted process of evaluation. Clinical topics cover spasticity, dyskinesia, growth monitoring, neuroimaging, genetic considerations, and associated conditions such as epilepsy, pain, and oral health.
Advanced levels focus on management strategies, including oral medications, injections, intrathecal baclofen therapy, selective dorsal rhizotomy, and deep brain stimulation. Learners also gain insight into therapy-based interventions, lifespan care, and transitional planning, ensuring a full spectrum of knowledge for professionals working with individuals across childhood, adolescence, and adulthood.
The CP course spans more than 20 topics across five levels of instruction. Levels 1 and 2 provide foundational knowledge beneficial for allied professionals and medical professionals, including educators, social workers, therapists, and psychologists.
Levels 3 to 5 shift to a more clinical focus, offering advanced insights geared toward medical doctors and sub-specialists.
Course Editor
Heather Riordan, MD is a pediatric neurologist at Kennedy Krieger Institute and Associate Professor of Neurology at the Johns Hopkins University School of Medicine. She specializes in the care of children with cerebral palsy and other neurodevelopmental disorders. Dr. Riordan has extensive experience in diagnosis, management, and long-term care planning for children with CP, with research and clinical interests that include spasticity management and the transition of care into adulthood.
Content, Featured Experts, and Learner Groups
Level |
Neurodevelopmental Topic Content |
Featured Expert |
Learner Group(s) |
---|---|---|---|
Level 1
|
1.1 Defining Cerebral Palsy |
Heather Riordan, MD. |
Allied professionals Medical Professionals Sub-Specialist Professionals
|
1.2 Epidemiology of Cerebral Palsy |
Senaya Shenoy, MSPH. |
||
1.3 Pathophysiology of IVH and PVL |
April Sharp, MD. |
||
Level 2 |
2.1 Early Identification of CP |
Vera Joanna Burton, MD, PhD. |
Allied professionals Medical Professionals Sub-Specialist Professionals |
2.2 Hip Screening and Surveillance |
Emily Hillaker, DO. |
||
Level 3
|
3.1 Cerebral Palsy Evaluation: Art and Science |
Alec Hoon, MD, MPH. |
Medical Professionals Sub-Specialist Professionals
|
3.2 Hip Screening |
Emily Hillaker, DO. |
||
3.3 Examining Spasticity and Dyskinesia |
Vincent Shieh, MD. |
||
3.4 Monitoring Growth in CP |
Patricia Miller, MS, RD, CSP, LDN, FAND. |
||
3.5 Neuroimaging in CP |
Paul Salib, MPH. |
||
3.6 Genetic Causes in CP |
Alexis Heidlebaugh, ScM, CGC. |
||
3.7 Neuropsychological Conditions in CP |
Gwendolyn Gerner, PsyD. |
||
3.8 Pain in CP |
Eric Chin, MD. |
||
3.9 Neuropsychiatry in CP |
Aaron J. Hauptman, MD. |
||
3.10 Osteopenia in Children with Cerebral Palsy |
Cristina L Sadowsky, MD. |
||
3.11 Oral Health in CP |
Erica Caffrey, DDS. |
||
3.12 Epilepsy in CP |
Siddharth Gupta, M.B.B.S. |
||
Level 4
|
4.1 Managing Dyskinetic CP |
Shannon Dean, MD PhD. |
Medical Professionals Sub-Specialist Professionals
|
4.2 Oral Medications and Injections for Spasticity Management |
Marisa Flavin, MD. |
||
4.3 Intrathecal Baclofen (ITB) Therapy use in Cerebral Palsy |
Stephen A. Nichols, MD. |
||
4.4 Selective Dorsal Rhizotomy |
Shenandoah Robinson, MD, FAANS, FAAP. |
||
4.5 Deep Brain Stimulation Therapy in Cerebral Palsy Patients |
Lauryn Currens, MD. |
||
4.6 Effective Therapy Options for Managing Cerebral Palsy |
Ariel Jones, MS, OTR/L. Karen Good, PT, OCS, PCS. |
||
Level 5 |
5.1 Lifespan Care in CP |
Heather Riordan, MD. |
Medical Professionals Sub-Specialist Professionals |
5.2 Transitional Care in CP | Jessica De Curtis Fernandez, MD. | ||
5.3 CP in the School Environment |
Brooke Kimbrell, MD MSE. |
What is the KIND Curriculum?
Terms of Use & Privacy Policy
The Learning Materials are intended only to provide general information and need to be adapted for individualized patient care based on each practitioners’ professional judgment, unique patient circumstances, and other pertinent factors. The Learning Materials are not intended to constitute general medical advice or treatment or advice or treatment for any particular patient. The Learning Materials are not intended to create a doctor-patient relationship between/among Kennedy Krieger Institute, its physicians and individual patients or their family members or caregivers. Kennedy Krieger Institute makes no warranty, expressed or implied, with respect to the currency, completeness, applicability, or accuracy of the Learning Materials. To the extent that the Learning Materials include information regarding drug dosing, every effort will be made to identify when drug or medical device information included in the Learning Materials is not in agreement with FDA approval or guidance. However, it is the responsibility of the practitioner to ascertain FDA dosing recommendations and approval status of prescribed drugs and devices in their clinical practices.
The Learning Materials are protected by copyright laws and in some cases patent laws, and all rights are reserved under such laws. No part of the Learning Materials may be reproduced in any form by any means, or utilized in any other way, absent prior written permission from the copyright owner. |